Amyloid is everywhere, but new treatments could stop the toxic build up
Technology tamfitronics Amyloid deposits are present in the brains of cognitively impaired individuals, but also accumulate throughout the body. Some biotechs aim to keep these misfolded proteins in check to treat a range of diseases, including heart failure, ALS and Alzheimer’s disease. By late November, the US Food and Drug Administration (FDA) will decide whether to approve a highly anticipated new drug for treating a form of amyloid buildup that leads to heart failure. BridgeBio has developed acoramidis for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM), an important but often undiagnosed cause of heart failure that has become a significant focus for drug developers. Alnylam Pharmaceuticals is targeting this protein misfolding condition with another treatment option, Amvuttra...
